Get started
Author

Adam Kopoń

Observed names: A Kopon, A Kopoń, Adam Kopon
OpenAlex ID: A5017194976
Risankizumab for Ulcerative Colitis
2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 134
PDF
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
2024 · David T Rubin, Jessica R Allegretti, et al. · The Lancet · 113
PDF
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
2023 · Laurent Peyrin-Biroulet, Jessica R. Allegretti, et al. · Gastroenterology · 104
PDF
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis
2020 · Silvio Danese, Markus F. Neurath, et al. · Clinical Gastroenterology and Hepatology · 99
PDF
OP006 Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study
2018 · S Danese, M Neurath, et al. · Journal of Crohn s and Colitis · 24
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
2026 · Millie Long, Jessica R Allegretti, et al. · ˜The œLancet. Gastroenterology & hepatology · 9
DOP11 Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial
2024 · V Jairath, G Zou, et al. · Journal of Crohn s and Colitis · 8
PDF
P658 Safety and efficacy of MH002, an optimized live biotherapeutic product, for the treatment of mild to moderate ulcerative colitis: a first-in-disease, double-blind, randomized clinical trial
2024 · S Vermeire, P Dewint, et al. · Journal of Crohn s and Colitis · 5
PDF
813 - Apremilast for Active Ulcerative Colitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
2018 · Silvio Danese, Markus Neurath, et al. · Gastroenterology · 4
DOP050 Target achievement after 48 weeks of vedolizumab treatment in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial
2025 · V Jairath, G Zou, et al. · Journal of Crohn s and Colitis · 3
1114: Target Achievement After 48 Weeks of Vedolizumab Treatment in Patients With Moderate to Severe Ulcerative Colitis: an Interim Analysis From the Verdict Trial
2025 · Vipul Jairath, GY Zou, et al. · Gastroenterology · 2
905 Disease Clearance After 16 Weeks of Treatment With Vedolizumab in Patients With Moderate to Severe Ulcerative Colitis: an Interim Analysis From the Verdict Trial
2024 · Vipul Jairath, GY Zou, et al. · Gastroenterology · 2
988 Safety and Efficacy of Mh002, an Optimized Live Biotherapeutic Product, for the Treatment of Mild to Moderate Ulcerative Colitis: a First-in-disease, Double-blind, Randomized Clinical Trial
2024 · Séverine Vermeire, Pieter Dewint, et al. · Gastroenterology · 2
DOP094 Improvement in biomarkers in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trial
2025 · V Jairath, P Bossuyt, et al. · Journal of Crohn s and Colitis · 1
PDF
DOP007 Change in Histological inflammation in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trial
2025 · V Jairath, L Peyrin-Biroulet, et al. · Journal of Crohn s and Colitis · 1
Su1941: IMPROVEMENT IN BIOMARKERS IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH VEDOLIZUMAB: RESULTS FROM THE CONTINUING VERDICT TRIAL
2025 · Vipul Jairath, Peter Bossuyt, et al. · Gastroenterology
Works count: 16
Citation count: 511
H-index: 7
I10-index: 5
Year
Topic
Type